Interview with the Innovators

Moving Multiple Myeloma Treatment from IV Infusions to SQ Injections

Video Library

Featuring:

Charise Gleason, MSN, NP-BC, AOCNP
Advanced Practice Provider Chief, Winship Cancer Institute,
Emory University,
Atlanta, GA
Chelsea Sprouse, RN-BSN, MSN, NP-C
Nurse Practitioner, Inpatient and Outpatient Malignant Hematology,
Levine Cancer Institute,
Charlotte, NC
Kathryn Maples, PharmD, BCOP
Clinical Pharmacy Specialist, Multiple Myeloma, and PGY2 Oncology Residency Research Coordinator,
Winship Cancer Institute, Emory Healthcare,
Atlanta, GA

Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, discuss their perspectives on using SQ treatments for MM, including the benefits for the patients, along with a requirement for education and training for nurses with respect to delivering a high-volume injection into the SQ space.

Related Items

Managing Neuropathy That May Accompany ADC Therapy in Breast Cancer
By Tajuana Bradley, MS, FNP-BC; Abbey J. Kaler, MS, APRN, FNP-C
Video Library
How can clinicians monitor and manage neuropathy in patients with breast cancer receiving ADC therapy? In this video, Tajuana Bradley, MS, FNP-BC, and Abbey J. Kaler, MS, APRN, FNP-C, discuss practical approaches to initial and ongoing assessments, concomitant medication, and patient education on symptoms that should be reported promptly.
Managing Hematologic Toxicities With ADC Therapy in Breast Cancer
By Tajuana Bradley, MS, FNP-BC; Abbey J. Kaler, MS, APRN, FNP-C
Video Library
How can clinicians monitor and manage hematologic toxicities in patients with breast cancer receiving ADC therapy? In this video, Tajuana Bradley, MS, FNP-BC, and Abbey J. Kaler, MS, APRN, FNP-C, discuss practical approaches to laboratory monitoring and the assessment and management of neutropenia, thrombocytopenia, and anemia, including toxicity grading, treatment modifications, and patient education on symptoms that should be reported promptly.
Assessing Patient Risk Before ADC Therapy in Breast Cancer
By Tajuana Bradley, MS, FNP-BC; Abbey J. Kaler, MS, APRN, FNP-C
Video Library
How can early identification of patient-specific risk factors help optimize patient outcomes and proactively manage toxicity with ADC therapy? In this video, Tajuana Bradley, DNP, FNP-BC, AOCNP, and Abbey Kaler, PA-C, discuss approaches to evaluating baseline risk factors, identifying patients who may be at increased risk for key ADC-related toxicities, and implementing monitoring, multidisciplinary care, and patient education strategies at treatment initiation.
Journal of Oncology Navigation & Survivorship
JONS

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
    Profession or Role
    Primary Specialty or Disease State
    Country